2024 Annual Meeting | PL7 - Neurology Year in Review Plenary Session

Date Thursday 04/18/24

Time 09:15 AM - 11:30 AM MDT Add To Calendar

Location Colorado Convention Center | Bellco Theatre

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Plenary Session

Director(s) Claire Riley, MD, FAAN

Topic(s) Education, Research, and Methodology

Learning Objectives Six speakers will each focus on the latest developments of interest to the clinician that have occurred in a specific subspecialty topic.

CME Available 2.25 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
09:15 AM - 09:35 AM MDT	Speaker	Car-T Therapy: Indications for Use and Clinical Management Bianca Santomasso, MD
09:35 AM - 09:55 AM MDT	Speaker	Gene Transfer Therapy: Is it Safe? Julie A. Parsons, MD
09:55 AM - 10:15 AM MDT	Speaker	Migraine Management in Special Populations Eric Kaiser, MD, PhD
10:15 AM - 10:35 AM MDT	Speaker	The Current State of Long-COVID: Where Does the Autonomic Nervous System Fit In? David S. Goldstein, MD, PhD
10:35 AM - 10:55 AM MDT	Speaker	Transcranial Magnetic Stimulation Updates Dylan J. Edwards
10:55 AM - 11:15 AM MDT	Speaker	The Future of ALS Jinsy Andrews, MD, FAAN

Faculty Disclosures
Claire Riley, MD, FAAN	Dr. Riley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Riley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viracta. Dr. Riley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics.
Bianca Santomasso, MD	Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Pharmaceuticals. Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb. Dr. Santomasso has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kite/Gilead. Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for In8bio. Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen Pharmaceuticals. Dr. Santomasso has received personal compensation in the range of $500-$4,999 for serving as a Committee Member Activity with National Comprehensive Cancer Network.
Eric Kaiser, MD, PhD	The institution of Dr. Kaiser has received research support from Amgen. Dr. Kaiser has received intellectual property interests from a discovery or technology relating to health care.
Jinsy Andrews, MD, FAAN	Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Life Sciences. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as a Consultant for Cytokinetics. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apellis . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revalasio . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AL-S Pharma. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Quralis . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Neurosense. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Akava. The institution of Dr. Andrews has received research support from Amylyx. The institution of Dr. Andrews has received research support from Biogen . The institution of Dr. Andrews has received research support from Cytokinetics . The institution of Dr. Andrews has received research support from NIH . The institution of Dr. Andrews has received research support from Biohaven/Platform Trial. The institution of Dr. Andrews has received research support from Clene/Platform Trial . The institution of Dr. Andrews has received research support from Ra Pharma/Platform Trial . The institution of Dr. Andrews has received research support from Prilenia/Platform Trial . Dr. Andrews has received research support from ALS Association . Dr. Andrews has a non-compensated relationship as a Board of Trustee Member with ALS Association that is relevant to AAN interests or activities.
Dylan J. Edwards	No disclosure on file
David S. Goldstein, MD, PhD	Dr. Goldstein has received publishing royalties from a publication relating to health care.
Julie A. Parsons, MD	Dr. Parsons has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Parsons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Parsons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Parsons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ultragenex. The institution of Dr. Parsons has received research support from AveXis. The institution of Dr. Parsons has received research support from Biogen. The institution of Dr. Parsons has received research support from Scholar Rock. The institution of Dr. Parsons has received research support from Biohaven. The institution of Dr. Parsons has received research support from PTC Therapeutics. The institution of Dr. Parsons has received research support from Novartis.